Our strengths

With an experienced team and excellent facilities, our facility has the skills and capacity to run all types of high-quality complex trials across the majority of disease areas.

Clinical trials taking place at NIHR Leeds CRF recruit from a patient population of over five million in the Yorkshire and Humber region, which is geographically, economically and ethnically diverse. Leeds Teaching Hospitals Trust is one of the biggest NHS trusts in the country and one of the largest teaching hospitals in Europe, offering a full range of acute and non-acute adult and paediatric services and treating 1.5 million people every year. It serves a local population of 780,000, and provides specialist care to 5.4 million people, in particular services for cancer, haematology, cardiology, paediatrics, neuroscience and in specialist surgery.

Leeds Teaching Hospitals is a founding NHS partner of the NIHR Cancer Research Network and the NIHR Comprehensive Clinical Research Network, which has helped drive a significant improvement in patient access to research, with over 12,000 patients taking part in clinical trials each year. Leeds Teaching Hospitals is consistently amongst the top ten NHS Trusts in England for the number of NIHR portfolio trials and numbers of patients recruited.

NIHR Leeds CRF is part of a strong medical and clinical research base at Leeds Teaching Hospitals and its partner institution, the University of Leeds, which can jointly boast world class academic and clinical centres spanning research from basic science through to applied health services. The University of Leeds is one of the UK’s largest universities, a member of the elite 'Russell Group' and the impact of Leeds’ research was recently rated the highest in the UK outside London, Oxford and Cambridge.

We work closely with other research centres across the Trust and the University, including:

We have particular expertise in generating high quality data for and from our clinical trials, using techniques such as accurate phenotyping of patients, molecular genetic analysis of blood malignancies and high throughput screening and sequencing of tumours.